Biotech · Private company · Pittsboro, NC, US
Enfuego Therapeutics Inc.
Track this companyFree. Adds Enfuego Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Overcoming Adaptive KRAS Inhibitor Resistance with Ligand-Directed KRAS G12V-panTEAD ChimerasFiscal year 2026 · $311.7KNIH RePORTER 1R44CA314597-01 · fetched Nov 12, 2026
- Ligand-Directed KRAS G12V Mutant-Specific TherapeuticsFiscal year 2025 · $919KNIH RePORTER 5R44CA284932-03 · fetched Nov 12, 2026
- Ligand-Directed KRAS G12V Mutant-Specific TherapeuticsFiscal year 2024 · $919KNIH RePORTER 4R44CA284932-02 · fetched Nov 12, 2026